Cargando…

Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting

The neutrophil to lymphocyte ratio (NLR) is a promising predictive and prognostic factor in breast cancer. We investigated its ability to predict disease-free survival (DFS) and overall survival (OS) in patients with luminal A- or luminal B-HER2-negative breast cancer who received neoadjuvant chemot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grassadonia, Antonino, Graziano, Vincenzo, Iezzi, Laura, Vici, Patrizia, Barba, Maddalena, Pizzuti, Laura, Cicero, Giuseppe, Krasniqi, Eriseld, Mazzotta, Marco, Marinelli, Daniele, Amodio, Antonella, Natoli, Clara, Tinari, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303552/ https://www.ncbi.nlm.nih.gov/pubmed/34359855 http://dx.doi.org/10.3390/cells10071685

Ejemplares similares

Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials
por: Marinelli, Daniele, et al.
Publicado: (2020)

Burnout of health care providers during the COVID-19 pandemic: Focus on Medical Oncologists
por: Vici, Patrizia, et al.
Publicado: (2021)

Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives
por: Barchiesi, Giacomo, et al.
Publicado: (2020)

Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer
por: Mazzotta, Marco, et al.
Publicado: (2019)

Case report: 5-year progression free survival and complete liver response in a patient with metastatic breast cancer treated with everolimus plus exemestane
por: Krasniqi, Eriseld, et al.
Publicado: (2020)

Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors
por: Vici, Patrizia, et al.
Publicado: (2020)

Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios
por: Pizzuti, Laura, et al.
Publicado: (2019)

Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting
por: Di Benedetto, Anna, et al.
Publicado: (2019)

Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials
por: Grassadonia, Antonino, et al.
Publicado: (2018)

COVID‐19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience
por: Barba, Maddalena, et al.
Publicado: (2021)

A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression
por: Peri, Marta, et al.
Publicado: (2019)

Highly durable response to capecitabine in patient with metastatic estrogen receptor positive breast cancer: A case report
por: Barchiesi, Giacomo, et al.
Publicado: (2019)

Cancer patients and coronavirus disease 2019: evidence in context
por: Barba, Maddalena, et al.
Publicado: (2020)

Effect of Targeted Agents on the Endocrine Response of Breast Cancer in the Neoadjuvant Setting: A Systematic Review
por: Grassadonia, Antonino, et al.
Publicado: (2015)

Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
por: Natoli, Clara, et al.
Publicado: (2013)

Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial
por: Moscetti, Luca, et al.
Publicado: (2017)

Observational Multicenter Study on the Prognostic Relevance of Coagulation Activation in Risk Assessment and Stratification in Locally Advanced Breast Cancer. Outline of the ARIAS Trial
por: Pizzuti, Laura, et al.
Publicado: (2020)

MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study
por: Krasniqi, E., et al.
Publicado: (2021)

Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review
por: Sperduti, Isabella, et al.
Publicado: (2013)

The Impact of the Hippo Pathway and Cell Metabolism on Pathological Complete Response in Locally Advanced Her2+ Breast Cancer: The TRISKELE Multicenter Prospective Study
por: Krasniqi, Eriseld, et al.
Publicado: (2022)

Long-Term Outcome of Neoadjuvant Endocrine Therapy with Aromatase Inhibitors in Elderly Women with Hormone Receptor-Positive Breast Cancer
por: Grassadonia, Antonino, et al.
Publicado: (2014)

Is the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies?
por: Graziano, Vincenzo, et al.
Publicado: (2015)

Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis
por: Vici, Patrizia, et al.
Publicado: (2015)

Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study
por: Grassadonia, Antonino, et al.
Publicado: (2019)

Circulating Autoantibodies to LGALS3BP: A Novel Biomarker for Cancer
por: Grassadonia, Antonino, et al.
Publicado: (2013)

Breast Cancer “Tailored Follow-up” in Italian Oncology Units: A Web-Based Survey
por: Natoli, Clara, et al.
Publicado: (2014)

Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice
por: Angelucci, Domenico, et al.
Publicado: (2012)

Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy
por: Vici, Patrizia, et al.
Publicado: (2016)

Neoadjuvant Sequential Docetaxel Followed by High‐Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial
por: Pizzuti, Laura, et al.
Publicado: (2016)

Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies
por: Grassadonia, Antonino, et al.
Publicado: (2013)

Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA Exploration
por: Krasniqi, Eriseld, et al.
Publicado: (2022)

Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives
por: Krasniqi, E., et al.
Publicado: (2019)

Circulating HPV DNA in the Management of Oropharyngeal and Cervical Cancers: Current Knowledge and Future Perspectives
por: Krasniqi, Eriseld, et al.
Publicado: (2021)

Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study
por: Vici, Patrizia, et al.
Publicado: (2014)

Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting
por: Pizzuti, Laura, et al.
Publicado: (2017)

Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progression
por: Grassadonia, Antonino, et al.
Publicado: (2021)

Correction: Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progression
por: Grassadonia, Antonino, et al.
Publicado: (2021)

FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort
por: Maugeri-Saccà, Marcello, et al.
Publicado: (2013)

Multicohort and cross‐platform validation of a prognostic Wnt signature in colorectal cancer
por: Goeman, Frauke, et al.
Publicado: (2020)

Role of Chemotherapy in Vulvar Cancers: Time to Rethink Standard of Care?
por: Mazzotta, Marco, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1o1os7m9si28rdh88i6fbo1vgt